DexCom: Clinical Data Could Redefine the Market for Non-Insulin Type 2 Diabetics!
Reading Time: 3 minutes
DexCom aims for a revenue of up to $5.25 billion for the entire year 2026. The CONNECT study demonstrates the clinical benefits of CGM in non-insulin-dependent diabetics for the first time. The study data show strong synergies between sensor use and GLP-1 therapies. Fundamental Stability Through Market Penetration The business model of DexCom (DXCM) focuses on continuous glucose monitoring (CGM) systems. While the company has historically been anchored in Type 1 diabetics, growth is now increasingly shifting to broader patient groups....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
